OncoMatch/Clinical Trials/NCT07648069
Tumor Neoantigen Vaccine SarVac Combined With Tumor Specific Lymphocyte Reinfusion in the Treatment of Advanced Sarcoma
Is NCT07648069 recruiting? Yes, currently enrolling (Jul 2026). This Phase 1 trial studies multiple treatments including Neoantigen vaccine + specific lymphocytes + anti-PD1 antibody and Neoantigen vaccine + anti-PD1 antibody for soft tissue sarcoma (sts).
Treatment: Neoantigen vaccine + specific lymphocytes + anti-PD1 antibody · Neoantigen vaccine + anti-PD1 antibody — The primary objective of this trial is to evaluate the safety and tolerability of the tumor neoantigen vaccine (SarcVac) in combination with a PD-1 antibody, with or without tumor-specific lymphocytes, in patients with advanced bone and soft tissue sarcoma who have failed first-line treatment. The secondary objectives are to assess the preliminary efficacy of SarcVac combined with a PD-1 antibody, with or without tumor-specific lymphocytes, in these patients and to evaluate whether the vaccine's efficacy demonstrates dose dependency.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Sarcoma
Osteosarcoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: first-line therapy
Patients with first-line treatment failure
Cannot have received: tumor vaccine
No previous tumor vaccine treatment
Cannot have received: anti-PD-1 therapy
no previous treatment with PD-1 antibody
Lab requirements
Blood counts
White blood cell count ≥ 3.0 × 10^9 / L; absolute neutrophil count (ANC) ≥ 1.5 × 10^9 / L (without GCSF support); absolute lymphocyte count (ALC) ≥ 1.0 × 10^9 / L; platelet (PLT) ≥ 75 × 10^9 / L; hemoglobin ≥ 90g / dL (no blood transfusion in the past 7 days)
Kidney function
serum creatinine ≤ 1.5 × ULN; 24-hour creatinine clearance rate ≥ 60 mL / min
Liver function
Aspartate Aminotransferase (AST/SGOT) ≤ 2 × ULN; Alanine Aminotransferase (ALT/SGPT) ≤ 2 × ULN; total bilirubin (TBIL) ≤ 1 × ULN
Cardiac function
echocardiography showed left ventricular ejection fraction ≥ 50 %
The results of laboratory tests should meet at least the following indicators : ... echocardiography showed left ventricular ejection fraction ≥ 50 %
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07648069 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior tumor vaccine, anti-PD-1 therapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages